These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Meissner EG Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883 [No Abstract] [Full Text] [Related]
4. Emerging antiviral drugs for hepatitis C virus. Enomoto M; Tamori A; Kawada N Rev Recent Clin Trials; 2009 Sep; 4(3):179-84. PubMed ID: 20028330 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560 [TBL] [Abstract][Full Text] [Related]
6. Clinical trial investigates two experimental HCV drugs. AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017 [No Abstract] [Full Text] [Related]
7. Hepatitis C virus-specific directly acting antiviral drugs. Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206 [TBL] [Abstract][Full Text] [Related]
8. Antiviral Research--16th International Congress: HBV and HCV. 27 April-1 May 2003, Savannah, GA, USA. Smee D IDrugs; 2003 Jun; 6(6):518-21. PubMed ID: 12861975 [No Abstract] [Full Text] [Related]
9. Understanding the molecular targets for new therapeutical agents in hepatitis c infection. Vagu C; Sultana C; Ruţă S Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011 [TBL] [Abstract][Full Text] [Related]
10. [The molecular biology of hepatitis C virus]. Koutsoudakis G; Forns X; Pérez-Del-Pulgar S Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024 [TBL] [Abstract][Full Text] [Related]
11. [Current advances in hepatitis C treatment]. Cisneros-Garza LE Salud Publica Mex; 2011; 53 Suppl 1():S52-60. PubMed ID: 21877074 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of HCV antiviral drug resistance. Welsch C; Zeuzem S Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109 [TBL] [Abstract][Full Text] [Related]
14. Ribavirin: is it a mutagen for hepatitis C virus? Perelson AS; Layden TJ Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896 [No Abstract] [Full Text] [Related]
15. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment]. Puig-Basagoiti F; Sáiz JC Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621 [No Abstract] [Full Text] [Related]
16. Inhibitor Development against p7 Channel in Hepatitis C Virus. Wei S; Hu X; Du L; Zhao L; Xue H; Liu C; Chou JJ; Zhong J; Tong Y; Wang S; OuYang B Molecules; 2021 Mar; 26(5):. PubMed ID: 33802584 [TBL] [Abstract][Full Text] [Related]
17. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Gentile I; Buonomo AR; Zappulo E; Coppola N; Borgia G Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1179-86. PubMed ID: 25096404 [TBL] [Abstract][Full Text] [Related]
18. Introduction to hepatitis C virus (HCV) therapies special thematic issue. Meanwell NA; Watkins WJ J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173 [No Abstract] [Full Text] [Related]
19. New therapies on the horizon for hepatitis C: are we close? De Francesco R; Rice CM Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference. Buti M IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952 [No Abstract] [Full Text] [Related] [Next] [New Search]